The Company’s proprietary technology consists of non-replicating adenovirus and bacterial vectors that can deliver antigens non-invasively (to the nasal passages or to the skin) to elicit a protective immune response. The nasal mucosa and the skin contain cells that participate in the body’s protection mechanism against disease causing pathogens. Vaxin’s technology harnesses this pre-existing feature of our immune system. CLICK FOR MORE INFORMATION

VAXIN AND CRUCELL ANNOUNCE COLLABORATION TO FIGHT ALZHEIMER’S DISEASE- November 13, 2008
Press Release

VAXIN TO PRESENT AT THE RODMAN & RENSHAW 1OTH ANNUAL HEALTHCARE CONFERENCE - November 5, 2008
Press Release

Vaxin begins pandemic flu study using Birmingham volunteers - October 8, 2008
The Birmingham News

VAXIN INITIATES PHASE I HUMAN STUDY OF H5N1 PANDEMIC FLU VACCINE - October 8, 2008
Press Release

VAXIN RECEIVES $100,000 GRANT FOR DEVELOPMENT OF ACNE VACCINE- September 18, 2008
Press Release

VAXIN AWARDED NIH FUNDING FOR AVIAN FLU VACCINE DEVELOPMENT- September 10, 2008 Press Release

Vaxin developing game-changing flu vaccine - August 26, 2008
TechJournal South

VAXIN’S PANDEMIC VACCINE SPOTLIGHTED- August 13, 2008
Press Release

Biotech firm Vaxin taps new CEO, looks for VC funds - August 8, 2008
Birmingham Business Journal